This Event has Passed
- Virtual
Biosimilars: Have We Reached an Inflection Point?
Where
Virtual
When
{{getUserDateTimezone("1790269200").singleDate}}
{{getUserDateTimezone("1790269200").time}} - {{getUserDateTimezone("1790272800").time}} {{getClientTimezoneName()}}
About
The first big wave of biosimilars has hit the market, and another crop of widely used medicines will soon face lower-cost competition. The Food and Drug Administration has been breaking down barriers for these copies in hopes of slashing drug spending. But shifting policies and a convoluted health system could upend recent progress. What’s next?
Sponsor Speaker
- Thomas Newcomer, senior vice president and head of US commercial, Samsung Bioepis
Featured Speakers
- Chris Brown, managing principal, McAteer
- Madelaine Feldman, M.D., FACR, Coalition of Rheumatology Organizations, VP Advocacy & Gov’t Affairs; clinical assistant professor of medicine, Tulane School of Medicine
- Michael A. Gonzales, independent healthcare consultant
- Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)
Sponsored By
Upcoming Events
Featuring the year's top voices driving innovation across biotech, pharma, health care, and life sciences.
